• Mutation; HGNC; HGNC:7765; NF1; Simple; p.Gln28Ter (c.82C>T); ClinVar=VCV000429015; Zygosity=Homozygous (PubMed=30737244).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Asn29Thrfs*15 (c.86delA); ClinVar=VCV000528243; Zygosity=Homozygous (PubMed=30737244).
  

PubMed=17406368; DOI=10.1038/sj.bjc.6603578; PMCID=PMC2360140
Rodrigues R.F., Roque L., Krug T., Leite V.
Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines.
Br. J. Cancer 96:1237-1245(2007)

PubMed=23833040; DOI=10.1210/jc.2013-2383; PMCID=PMC3763971
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)

PubMed=25365311; DOI=10.1210/jc.2014-2359; PMCID=PMC4318896
Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.-T., Chang W.J., Yang H.H., Ogawa S., Koeffler H.P.
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)

PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953; PMCID=PMC6522280
Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C., Copland J.A. 3rd, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)